Traumatic Brain Injury Exacerbates Neurodegenerative Pathology: Improvement with an Apolipoprotein E-Based Therapeutic
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Cognitive impairment is common following traumatic brain injury (TBI), and neuroinflammatory mechanisms may predispose to the development of neurodegenerative disease. Apolipoprotein E (apoE) polymorphisms modify neuroinflammatory responses, and influence both outcome from acute brain injury and the risk of developing neurodegenerative disease. We demonstrate that TBI accelerates neurodegenerative pathology in double-transgenic animals expressing the common human apoE alleles and mutated amyloid precursor protein, and that pathology is exacerbated in the presence of the apoE4 allele. The administration of an apoE-mimetic peptide markedly reduced the development of neurodegenerative pathology in mice homozygous for apoE3 as well as apoE3/E4 heterozygotes. These results demonstrate that TBI accelerates the cardinal neuropathological features of neurodegenerative disease, and establishes the potential for apoE mimetic therapies in reducing pathology associated with neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 2×
“…pathology seen following TBI, we utilized double-transgenic animals expressing both the human APOE3 or APOE4 polymorphism in the correct genetic locus (APOE-targeted replacement), and the mutant human APP (V717P), in a minigene driven by a platelet-derived growth factor (PDAPP; Games et al., 1995).”
InfluentialIntracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Carroll, L., Cassidy, J. D., Peloso, P., Borg, J., von Holst, H., Holm, L., Paniak, C., & Pépin, M. (2004) · Journal of Rehabilitation Medicine · doi:10.1080/16501960410023859 · Cited by 1,326
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“Interestingly, the presence of the human apoE protein retards extracellular amyloid deposition in non-injured PDAPP animals (Fagan et al., 2002; Holtzman et al., 2000).”
Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias
Plassman, B. L., Havlik, R. J., Steffens, D. C., Helms, M. J., Newman, T. N., Drosdick, D., Phillips, C., Gau, B. A., Welsh–Bohmer, K. A., Burke, J. R., et al. (2000) · Neurology · doi:10.1212/wnl.55.8.1158 · Cited by 896 · cited 1×
“…deficit may be a static phenomenon due to injury of preferentially susceptible hippocampal and cortical neurons, there is evidence that brain trauma may be associated with later development of neuro-degenerative disease in a subset of patients (Guo et al., 2000; Plassman et al., 2000).”
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · cited 2×
“Conversely, the possibility that APOE4 is associated with increased neuroinflammation is consistent with recent observations demonstrating that APOE4 was associated with an increase in vasogenic edema in a clinical trial of bapineuzumab, a monoclonal antibody designed to promote clearance of Ab (Salloway et al., 2009).”
Sullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., Quarfordt, S. H., & Maeda, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.17972 · Cited by 575 · cited 3×
“These TR animals express the human apoE3 or apoE4 protein isoforms at physiological levels in a temporal and spatial pattern similar to that observed in primates and humans (Sullivan et al., 1994, 1997).”
Self-citationRoberts, G. W., Gentleman, S. M., Lynch, A., Murray, L., Landon, M., & Graham, D. I. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.419 · Cited by 569 · cited 1×
“Alternatively, increased levels of A b associated with APOE4 may also have contributed to microglial activation (Nicoll et al., 1995; Roberts et al., 1994).”
Head injury and the risk of AD in the MIRAGE study
Guo, Z., Cupples, L. A., Kurz, A., Auerbach, S. H., Volicer, L., Chui, H., Green, R. C., Sadovnick, A. D., Duara, R., DeCarli, C., et al. (2000) · Neurology · doi:10.1212/wnl.54.6.1316 · Cited by 506 · cited 1×
“…deficit may be a static phenomenon due to injury of preferentially susceptible hippocampal and cortical neurons, there is evidence that brain trauma may be associated with later development of neuro-degenerative disease in a subset of patients (Guo et al., 2000; Plassman et al., 2000).”
Cited by
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Chen, S., Peng, J., Sherchan, P., Ma, Y., Xiang, S., Yan, F., Zhao, H., Jiang, Y., Wang, N., Zhang, J. H., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01853-x · Cited by 379
APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease
Michaelson, D. M. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.015 · Cited by 331
APOE genotype alters glial activation and loss of synaptic markers in mice
Zhu, Y., Nwabuisi‐Heath, E., Dumanis, S. B., Tai, L. M., Yu, C., Rebeck, G. W., & Ladu, M. J. (2012) · Glia · doi:10.1002/glia.22289 · Cited by 224
“For example, peptides based on the apoE receptor-binding domain decrease glial activation and reduce damage in traumatic brain injury (Laskowitz et al. 2010), promote axon regeneration after peripheral nerve injury (Li et al.”
BackgroundHuman APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition
Rodriguez, G. A., Tai, L. M., LaDu, M. J., & Rebeck, G. W. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-111 · Cited by 193
“APOE4 is associated with upregulated gene expression of pro-inflammatory cytokines following traumatic brain injury and lipopolysaccharide (LPS) treatment compared to APOE3 [30,43].”
BackgroundInfluential
Metadata
- Authors
- Laskowitz, D. T., Song, P., Wang, H., Mace, B., Sullivan, P. M., Vitek, M. P., & Dawson, H. N.
- Venue
- Journal of Neurotrauma
- Publisher
- SAGE Publications
- Published
- 2010-11
- Volume
- 27
- Issue
- 11
- Pages
- 1983-1995
- ISSN
- 0897-7151 (ISSN-L)
- 1557-9042
- OpenAlex
- W2061478691
- Cited by
- 92
- References
- 23
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Traumatic Brain Injury Exacerbates Neurodegenerative Pathology: Improvement with an Apolipoprotein E-Based Therapeutic. https://app.cochat.ai/papers/10.1089/neu.2010.1396
- The paper
- Laskowitz, D. T., Song, P., Wang, H., Mace, B., Sullivan, P. M., Vitek, M. P., & Dawson, H. N. (2010). Traumatic Brain Injury Exacerbates Neurodegenerative Pathology: Improvement with an Apolipoprotein E-Based Therapeutic. Journal of Neurotrauma. https://doi.org/10.1089/neu.2010.1396
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.